SU827064A1 - Method of prophylaxis endogenic infecting at acute leukosis - Google Patents

Method of prophylaxis endogenic infecting at acute leukosis Download PDF

Info

Publication number
SU827064A1
SU827064A1 SU792769498A SU2769498A SU827064A1 SU 827064 A1 SU827064 A1 SU 827064A1 SU 792769498 A SU792769498 A SU 792769498A SU 2769498 A SU2769498 A SU 2769498A SU 827064 A1 SU827064 A1 SU 827064A1
Authority
SU
USSR - Soviet Union
Prior art keywords
acute
endogenic
leukosis
infecting
prophylaxis
Prior art date
Application number
SU792769498A
Other languages
Russian (ru)
Inventor
Татьяна Васильевна Голосова
Вера Александровна Мартынова
Тамара Васильевна Толкачева
Евгений Михайлович Абакумов
Татьяна Леонидовна Котт
Original Assignee
Центральный Научно-Исследовательскийордена Ленина И Ордена Трудового Красногознамени Институт Гематологии И Переливаниякрови
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Центральный Научно-Исследовательскийордена Ленина И Ордена Трудового Красногознамени Институт Гематологии И Переливаниякрови filed Critical Центральный Научно-Исследовательскийордена Ленина И Ордена Трудового Красногознамени Институт Гематологии И Переливаниякрови
Priority to SU792769498A priority Critical patent/SU827064A1/en
Application granted granted Critical
Publication of SU827064A1 publication Critical patent/SU827064A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

бйфйдббактёрий высевались Ё количествах 10,0 Ig/r.Byfidbbacter were sown in quantities of 10.0 Ig / r.

Пример 4. У больного 3. 20 лет с острым лимфобластным лейкозом отмечено сниженное количество нормальных представителей бифидобактерий до 6,0 Ig/r и высевалось большое количество синегнойной палочки до 7,0 Ig/r. Этому больному сначала назначали синегнойиый фаг (2 курса ), после подавлени  роста Ps aeruginosa больной получал бифидумбактерин в течение 21 дн . После приема больным биологических препаратов отмечено исчезновение из кишечника синегнойной палочки и увеличение бифидобактерий до 8,0 Ig/r. Example 4. Patient 3. For 20 years with acute lymphoblastic leukemia, there was a reduced number of normal representatives of bifidobacteria up to 6.0 Ig / r and a large number of Pseudomonas bacillus was seeded to 7.0 Ig / r. This patient was first prescribed blue-necked phage (2 courses), after suppressing the growth of Ps aeruginosa, the patient received Bifidumbacterin for 21 days. After the patient received biological preparations, the disappearance of the pseudomonas bacillus and an increase in bifidobacteria to 8.0 Ig / r were noted.

Если нар ду со снижением бифидобактерий отмечены нарушени  и в коли-флоре, то вместо бифидумбактерина больным назначали прием бификола.If, along with a decrease in bifidobacteria, disturbances were also noted in the coli-flora, then instead of bifidumbacterin, patients were prescribed bifikol.

У всех больных, получавших бактерийные препараты в период проведени  цитостатической терапии, наблюдали восстановление нормальной флоры кишечника, инфекционные осложнени  у наблюдаемой группы больных не отмечались.In all patients who received bacterial preparations during the period of cytostatic therapy, restoration of the normal intestinal flora was observed; no infectious complications were observed in the observed group of patients.

Предлагаемый способ способствует востановлению экологического равновеси  кишечного биоценоза физиологическим путем, снижает возможность эндогенного инфицировани  организма больного наиболее опасными грамотрицательными микроорганизмами (синегнойиа  палочка, протей и др.), уменьшает риск возникновени  инфекционных осложнений у больных острыми лейкозами , которые в 70% случаев  вл ютс  непосредственной причиной гибели больных в период медикаментозной гипоплазии.The proposed method contributes to the restoration of the ecological balance of the intestinal biocenosis by physiological means, reduces the possibility of endogenous infection of the patient's body with the most dangerous gram-negative microorganisms (blue-collar, proteus, etc.), reduces the risk of infectious complications in patients with acute leukemia, which in 70% of cases are the direct cause death of patients in the period of drug hypoplasia.

Claims (1)

1. Preisler Н. D., Goldstein I. М. et al. Gastrointestinal sterelization in the Treatement of Patients with Aeute Lenkemia. Caucer (Philad). 1970, 26, 5, 1076, 1981.1. Preisler N. D., Goldstein I. M. et al. Gastrointestinal Sterelization in the Treatement of Patients with Aeute Lenkemia. Caucer (Philad). 1970, 26, 5, 1076, 1981.
SU792769498A 1979-05-17 1979-05-17 Method of prophylaxis endogenic infecting at acute leukosis SU827064A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU792769498A SU827064A1 (en) 1979-05-17 1979-05-17 Method of prophylaxis endogenic infecting at acute leukosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU792769498A SU827064A1 (en) 1979-05-17 1979-05-17 Method of prophylaxis endogenic infecting at acute leukosis

Publications (1)

Publication Number Publication Date
SU827064A1 true SU827064A1 (en) 1981-05-07

Family

ID=20829126

Family Applications (1)

Application Number Title Priority Date Filing Date
SU792769498A SU827064A1 (en) 1979-05-17 1979-05-17 Method of prophylaxis endogenic infecting at acute leukosis

Country Status (1)

Country Link
SU (1) SU827064A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4123330A1 (en) * 1991-07-15 1993-01-21 Gerhard Netz Per-anal bacteria introduction system for regeneration of bowel bacteria - includes accommodating bacteria in water-soluble, pref. gelatin casing prior to insertion via sleeve
US6942858B1 (en) * 1996-04-15 2005-09-13 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4123330A1 (en) * 1991-07-15 1993-01-21 Gerhard Netz Per-anal bacteria introduction system for regeneration of bowel bacteria - includes accommodating bacteria in water-soluble, pref. gelatin casing prior to insertion via sleeve
US6942858B1 (en) * 1996-04-15 2005-09-13 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections

Similar Documents

Publication Publication Date Title
Wallace Jr et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy
Neu et al. In vitro activity of chloramphenicol and thiamphenicol analogs
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
HUP0004412A2 (en) Use of heterocyclic vinylethers for the preparation of pharmaceutical compositions treating neurological disorders
Ein et al. Susceptibility and synergy studies of methicillin-resistant Staphylococcus epidermidis
Dreizen et al. Opportunistic gram-negative bacillary infections in leukemia: Oral manifestations during myelosuppression
Speller et al. Coagulase-negative staphylococci causing endocarditis after cardiac surgery
NZ334848A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases caused by fungi and bacteria
SU827064A1 (en) Method of prophylaxis endogenic infecting at acute leukosis
MX9708611A (en) Dialkyltiacumicin compounds.
Neu Infections due to gram-negative bacteria: an overview
Shinefield et al. Bacterial interference between strains of S. aureus
Powell et al. Resistant coagulase-negative staphylococci in hospital patients
Bogaerts et al. In vitro antimicrobial sensitivity of Neisseria gonorrhoeae from Rwanda.
Korbel et al. Use of prophylactic antibiotics in urethral instrumentation
Freeman Short-term adverse effects of antibiotic prophylaxis for open-heart surgery.
MY104109A (en) Antibacterial 9-deoxo-9a-allyl and propargyl-9a-aza-9a-homoerythromycin a derivatives.
EP0909759A3 (en) Individual stereoisomers of 7-(3-aminoalkyl)-1-pyrrolidinyl)-quinolones as antibacterial agents
Hussey et al. Serotypes and antimicrobial susceptibility of Haemophilus influenzae
Rein et al. Bacteroides necrotizing fasciitis of the upper extremity
Hughes et al. Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function—some preliminary results
La Scola et al. Aortoabdominal aneurysm infected by Yersinia enterocolitica serotype O: 9
Drabu et al. Teicoplanin in infections caused by methicillin-resistant staphylococci
Panwalker et al. Actinobacillus actinomycetemcomitans endocarditis in a patient with a prosthetic aortic valve
Navarro et al. Failure of accessory spleens to prevent infection following splenectomy